Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

BioCity Completes Enrollment of ETA Agonist Trial in Patients with IgA Nephropathy

publication date: Feb 26, 2024

BioCity Biopharma, a clinical-stage company located in Wuxi, has enrolled all 120 participants in the IgA nephropathy (IgAN) cohort of a Phase II clinical study its oral endothelin A (ETA)-receptor selective antagonist. SC0062 is being tested in two forms of chronic kidney disease: IgAN and diabetic kidney disease (DKD). The company expects to complete enrollment of the DKD cohort by the end of Q2 2024. SC0062 is an ETA receptor small molecule antagonist designed with high selectivity to ensure efficacy and avoid safety risks. BioCity develops differentiated therapeutics for cancer and autoimmune disorders including chronic kidney diseases. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital